Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis; one size does not fit all

AIDS

Volumn 19, Issue 14, 2005, Pages 1541-1543

  Brennan Benson, Paul ^a   Lyus, Richard ^a   Harrison, Tom ^a   Pakianathan, Mark ^a   Macallan, Derek ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SLEEP DISORDER; SOMNOLENCE; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 25844481461     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000183519.45137.a6     Document Type: Article

References (8)

1. Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009-1021.
2. Dean GL, Edwards SG, Ives JI, Matthews G, Fox E, Navaratne L, et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16:75-83.
3. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations, 1998. Thorax 1998; 53:536-548.
4. British HIV Association. BHIVA treatment guidelines for TB/HIV co-infection. 2004. Available at: www.bhiva.org. Accessed: July 2005
5. Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Alarcon-Gonzalez A, Gomez-Mateos J, Leon-Jimenez E, et al. Pharmacokinetic interactions between efavirenzand rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokine 2002; 41:681-690.
6. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-75.
7. Ribaudo H, Clifford D, Gulick R, Shikuma C, Klingman K, Snyder S, et al. Relationship between efavirenz pharmacokinetics, side effects, drug discontinuation, virologic response and race: results from ACTG A5095/A5097s. in: 77th Conference on Retroviruses and Opportunistic Infections. San Francisco, 8-11 February 2004 [Abstract 132].
8. Haas D, Ribaudo H, Kim R, Tierney C, Wilkinson G, Gulick R, et al. A common CYP2B variant is associated with efavirenz pharmacokinetics and central nervous system side effects: AACTG Study NWCS214. 77th Conference on Retroviruses and Opportunistic Infections. San Francisco, 8-11 February 2004 [Abstract 133].